A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MD / mixed dementia

[Related PubMed/MEDLINE]
Total Number of Papers: 57
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MD  (>> Co-occurring Abbreviation)
Long Form:   mixed dementia
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Autophagy and mitophagy biomarkers are reduced in sera of patients with Alzheimer's disease and mild cognitive impairment. AD, MCI, VaD
2019 Diagnostic accuracy of the Montreal Cognitive Assessment (MoCA) for cognitive screening in old age psychiatry: Determining cutoff scores in clinical practice. Avoiding spectrum bias caused by healthy controls. AUC, MCI, MoCA, NPV, PPV
2019 Introducing a Novel Approach for Evaluation and Monitoring of Brain Health Across Life Span Using Direct Non-invasive Brain Network Electrophysiology. DELPHI, EEG, TMS
2018 Clock Drawing Test: A Simple Scoring System for the Accurate Screening of Cognitive Impairment in Patients with Mild Cognitive Impairment and Dementia. AD, CDT, MCI, MMSE
2018 High Occurrence of Psychiatric Disorders and Suicidal Behavior Across Dementia Subtypes. AD, FTD, LBD, SPAN, VA, VD
2018 Use of Speech Analyses within a Mobile Application for the Assessment of Cognitive Impairment in Elderly People. AD, MCI, SCI
2017 Association of adiponectin, leptin and resistin with inflammatory markers and obesity in dementia. AD, IL-6, VaD
2017 Clinical Spectrum, Risk Factors, and Behavioral Abnormalities among Dementia Subtypes in a North Indian Population: A Hospital-Based Study. AD, FTD, PWD, VaD
2017 Plasma levels of soluble receptor for advanced glycation end products in Alzheimer's disease. AD, OD, sRAGE, VaD
10  2016 Comparison of neuropsychological profiles in patients with Alzheimer's disease and mixed dementia. AD, CDR, CREDOS
11  2016 Decreased arylesterase activity of paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases. CSF, HDL, LOAD, MCI, MS, PON1, VaD
12  2016 Evolution of the Antidepressant Prescribing in Alzheimer's Disease and Related Disorders Between 2010 and 2014: Results from the French National Database on Alzheimer's Disease (BNA). AD, VaD
13  2016 The CITIRIVAD Study: CITIcoline plus RIVAstigmine in Elderly Patients Affected with Dementia Study. AchEIs, AD, ADL, GDS, MMSE, NPI
14  2016 [Clinical and neuropsychological features of Alzheimer's disease in the combination with cerebrovascular disease]. ACE-R, CVD, MoCA
15  2016 [Cognitive rehabilitation in early stage Alzheimer's disease]. CR, MCI
16  2015 Validation of the Montreal Cognitive Assessment (MoCA) in Spanish as a screening tool for mild cognitive impairment and mild dementia in patients over 65 years old in Bogota, Colombia. MCI, MoCA, MoCA-S
17  2014 Functional disorganization of small-world brain networks in mild Alzheimer's Disease and amnestic Mild Cognitive Impairment: an EEG study using Relative Wavelet Entropy (RWE). AD, aMCI, EEG, ODWT, RWE, SW
18  2014 [Clinical, neuropsychological and neuroimaging features of patients with mixed dementia]. AD
19  2013 Clinical and autonomic profile of patients with Alzheimer's disease and mixed dementia patients. HR, LF
20  2013 Neuropsychiatric Symptoms (NPS) in patients with pure Vascular Dementia (VaD) and Mixed Dementia (MD) from a memory outpatient clinic in southeast Brazil. NPS, VaD, VCI
21  2013 Paraoxonase 1 (PON1) gene-108C>T and p.Q192R polymorphisms and arylesterase activity of the enzyme in patients with dementia. AD, PON1
22  2013 Patterns of neuropsychological impairment in Alzheimer's disease and mixed dementia. AD, CVD
23  2013 [The importance of folic acid deficiency in the pathogenesis of vascular, mixed and Alzheimer's disease dementia]. AD, CDR, FOL, MMSE, VaD
24  2012 DAD-6: A 6-ltem version of the Disability Assessment for Dementia scale which may differentiate Alzheimer's disease and mild cognitive impairment from controls. DAD, MCI
25  2012 Early biomarkers for post-stroke cognitive impairment. NEP, sRAGE, VaD, VCIND
26  2012 Validation of the neurobehavioral cognitive status examination and the Rivermead Behavioural Memory Test in investigations of dementia. MCI, MMSE
27  2011 Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. AD, CSF, H-FABP, MBP, NFL, SVD, t-tau, VaD
28  2011 Mild cognitive impairment, degenerative and vascular dementia as predictors of intra-hospital, short- and long-term mortality in the oldest old. AD, MCI, VaD
29  2010 Cognitive profiles of incipient dementia in the Goteborg MCI study. AD, MCI, VaD
30  2010 Management of mixed dementia. AD, VaD
31  2010 Telomere length and ApoE polymorphism in mild cognitive impairment, degenerative and vascular dementia. AD, MCI
32  2009 A possible role of atrial fibrillation as a risk factor for dementia. AD, ADL, AF, CDR, IADL, MMSE, VaD
33  2009 CSF biomarker profile and diagnostic value in vascular dementia. AD, CSF, ELISA, VD
34  2009 The role of the -427T/C apolipoprotein E promoter polymorphism in the pathogenesis of Alzheimer's disease, vascular dementia and mixed dementia. AD
35  2008 Demented versus non-demented very old inpatients: the same comorbidities but poorer functional and nutritional status. AD, ADL, BMI, CCI, FIM, IADL, MCI, MNA, VaD
36  2008 Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia. AD, ADC, Cho, Cr, DeMCI, DWI, LBD, LOC, MCI, mI, MRS, NAA, PCG, PI, VaMCI
37  2008 [Evaluation of the capacity to drive in patients diagnosed of mild cognitive impairment and dementia]. MCI, RBANS, TMT, UFOV
38  2007 Brain type carnosinase in dementia: a pilot study. AD
39  2007 Effectiveness of a cognitive rehabilitation program in mild dementia (MD) and mild cognitive impairment (MCI): a case control study. AD, MCI
40  2007 Neuropathological evaluation of mixed dementia. AD, CVD, VaD
41  2007 Telephonic Remote Evaluation of Neuropsychological Deficits (TREND): longitudinal monitoring of elderly community-dwelling volunteers using touch-tone telephones. ADAS, CN, IVR, MCI, TREND
42  2007 Validation of clinical criteria for possible vascular dementia in the oldest-old. ADDTC, HIS, VaD
43  2006 Differences in risk factors for dementia with neurodegenerative traits and for vascular dementia. AD, APOE, IL, LDL
44  2006 Differential deposition of amyloid beta peptides in cerebral amyloid angiopathy associated with Alzheimer's disease and vascular dementia. AD, CAA, VaD
45  2006 Polymorphism of apolipoproteine E in relation with Alzheimer and vascular dementia. AD, CI, MMSE, OR, VD
46  2005 Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial. AD, BEHAVE-AD, CGIC
47  2005 [Mixed dementia: a neuropathologic point od view]. AD, VaD
48  2003 Important link between dementia subtype and apolipoprotein E: a meta-analysis. AD, APOE, LBD, NAVD, OR, VD
49  2002 Apolipoprotein E epsilon 4 allele frequency in demented and cognitively impaired patients with and without cerebrovascular disease. AD, APOE, CVD, MCI, NC, VaD
50  2002 Mixed dementia: epidemiology, diagnosis, and treatment. AD, VaD
51  2002 Neuropsychological differentiation of small vessel disease, Alzheimer's disease and mixed dementia. ---
52  1999 Apolipoprotein E phenotypes in demented and cognitively impaired patients with and without cerebrovascular disease. AD, APOE, CVD, MCI, VaD, VMCI
53  1996 Full-information models for multiple psychometric tests: annualized rates of change in normal aging and dementia. AD, BNT, DRS, MMSE, VD, WRB
54  1996 Vision in dementia: contrast effects. AD, VD
55  1995 Survival and dementia: a 7-year follow-up of an Italian elderly population. AD, MID
56  1991 Dementia: case ascertainment in a community survey. AD, MID
57  1990 [Neuropathologic study of 50 cases of senile dementia]. SDAT, VD